STREAMLINE HEALTH SOLUTIONS, INC. - 22% growth of SaaS revenue in the third quarter of fiscal 2023 compared to the third quarter of fiscal 2022
$400 thousand of Adjusted EBITDA generated in the third quarter of fiscal 2023 compared to($1.2) million during the third quarter of fiscal 2022$13.0 million of Booked SaaS ACV as ofOctober 31, 2023 ;$14.5 million of Booked SaaS ACV as ofDecember 13, 2023 ;$3.2 million unimplemented as ofDecember 13, 2023 - Updated breakeven SaaS Annual Recurring Revenue (ARR) run rate to
$15.5 million - Also announced 2,300 bed health system opted to leverage RevID’s automated charge reconciliation
The Company also announced that it has signed a new contract for the use of RevID with a 2,300-bed health system based in
Fiscal Third Quarter and Nine Months Ended
The following financial results have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”).
Total revenue for the third quarter of fiscal 2023 was
During the third quarter and first nine months of fiscal 2023, SaaS revenue grew
Net loss for the third quarter of fiscal 2023 was (
Fiscal Third Quarter and Nine Months Ended
Adjusted EBITDA for the third quarter of fiscal 2023 was
As of
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal.
The Company stated that due to its previously announced strategic restructuring it believes its adjusted EBITDA breakeven run rate is
Management Commentary
“Our restructuring has resulted in a leaner and more efficient organization. Streamline associates have worked hard to ensure our ability to retain existing clients, implement our backlog and accelerate sales growth,” stated
Conference Call
The Company will conduct a conference call on
A replay of the conference call will be available from
About Streamline
Non-GAAP Financial Measures
Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.
Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, share-based compensation expense, significant non-recurring operating expenses, restructuring expenses, impairment of goodwill and long-lived assets and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related alignment expenses, associate inducements, and professional and advisory fees. A table reconciling this measure to “loss from continuing operations” is included in this press release.
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal. Booked SaaS ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. Booked SaaS ACV is not intended to be a replacement for, or forecast of, revenue. There is no GAAP measure comparable to Booked SaaS ACV.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, anticipated bookings, recognition of revenue from contracts included in Booked SaaS ACV, anticipated cost savings from the recently announced strategic restructuring, expected improved implementation timelines and lower expenses for our clients, industry trends and market growth, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, achievement of a breakeven SaaS ARR run rate, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to generate cash from operations, the availability of additional debt and equity financing to fund the Company’s ongoing operations, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U.
Company Contact
Director, Investor Relations and FP&A
303-887-9625
jacob.goldberger@streamlinehealth.net
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(rounded to the nearest thousand dollars, except share and per share information)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenues: | ||||||||||||||||
| Software as a service | $ | 3,924,000 | $ | 3,209,000 | $ | 10,630,000 | $ | 9,157,000 | ||||||||
| Maintenance and support | 1,070,000 | 1,120,000 | 3,327,000 | 3,348,000 | ||||||||||||
| Professional fees and licenses | 1,139,000 | 1,888,000 | 3,278,000 | 5,639,000 | ||||||||||||
| Total revenues | 6,133,000 | 6,217,000 | 17,235,000 | 18,144,000 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of software as a service | 1,677,000 | 1,742,000 | 5,159,000 | 4,771,000 | ||||||||||||
| Cost of maintenance and support | 129,000 | 84,000 | 250,000 | 220,000 | ||||||||||||
| Cost of professional fees and licenses | 1,072,000 | 1,744,000 | 3,202,000 | 4,992,000 | ||||||||||||
| Selling, general and administrative expense | 4,122,000 | 4,055,000 | 12,079,000 | 12,629,000 | ||||||||||||
| Research and development | 1,304,000 | 1,754,000 | 4,310,000 | 4,527,000 | ||||||||||||
| Impairment of goodwill | 9,813,000 | — | 9,813,000 | — | ||||||||||||
| Impairment of long-lived assets | 963,000 | — | 963,000 | — | ||||||||||||
| Total operating expenses | 19,080,000 | 9,379,000 | 35,776,000 | 27,139,000 | ||||||||||||
| Operating loss | (12,947,000 | ) | (3,162,000 | ) | (18,541,000 | ) | (8,995,000 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | (266,000 | ) | (198,000 | ) | (781,000 | ) | (519,000 | ) | ||||||||
| Acquisition earnout valuation adjustments | 1,182,000 | 163,000 | 1,905,000 | 188,000 | ||||||||||||
| Other | — | 68,000 | 31,000 | 151,000 | ||||||||||||
| Loss before income taxes | (12,031,000 | ) | (3,129,000 | ) | (17,386,000 | ) | (9,175,000 | ) | ||||||||
| Income tax benefit (expense) | 120,000 | (9,000 | ) | 59,000 | (22,000 | ) | ||||||||||
| Net loss | $ | (11,911,000 | ) | $ | (3,138,000 | ) | $ | (17,327,000 | ) | $ | (9,197,000 | ) | ||||
| Basic and Diluted Earnings Per Share: | ||||||||||||||||
| Net loss per common share – basic and diluted | $ | (0.21 | ) | $ | (0.07 | ) | $ | (0.31 | ) | $ | (0.19 | ) | ||||
| Weighted average number of common shares – basic and diluted | 56,710,335 | 47,730,009 | 56,346,300 | 47,329,923 | ||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS
(rounded to the nearest thousand dollars, except share and per share information)
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,557,000 | $ | 6,598,000 | ||||
| Accounts receivable, net of allowance for credit losses of | 3,653,000 | 7,719,000 | ||||||
| Contract receivables | 763,000 | 960,000 | ||||||
| Prepaid and other current assets | 742,000 | 710,000 | ||||||
| Total current assets | 7,715,000 | 15,987,000 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net of accumulated amortization of | 94,000 | 79,000 | ||||||
| Right-of use asset for operating lease | — | 32,000 | ||||||
| Capitalized software development costs, net of accumulated amortization of | 6,248,000 | 5,846,000 | ||||||
| Intangible assets, net of accumulated amortization of | 12,479,000 | 14,793,000 | ||||||
| 13,276,000 | 23,089,000 | |||||||
| Other | 1,293,000 | 1,695,000 | ||||||
| Total non-current assets | 33,390,000 | 45,534,000 | ||||||
| Total assets | $ | 41,105,000 | $ | 61,521,000 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 736,000 | $ | 626,000 | ||||
| Accrued expenses | 2,883,000 | 3,265,000 | ||||||
| Current portion of term loan | 1,250,000 | 750,000 | ||||||
| Deferred revenues | 5,983,000 | 8,361,000 | ||||||
| Current portion of operating lease obligation | — | 35,000 | ||||||
| Acquisition earnout liability | 1,833,000 | 3,738,000 | ||||||
| Total current liabilities | 12,685,000 | 16,775,000 | ||||||
| Non-current liabilities: | ||||||||
| Term loan, net of current portion and deferred financing costs | 8,042,000 | 8,964,000 | ||||||
| Line of credit | 500,000 | — | ||||||
| Deferred revenues, less current portion | 127,000 | 167,000 | ||||||
| Other non-current liabilities | — | 104,000 | ||||||
| Total non-current liabilities | 8,669,000 | 9,235,000 | ||||||
| Total liabilities | 21,354,000 | 26,010,000 | ||||||
| Commitments and contingencies – Note 8 | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, | 588,000 | 576,000 | ||||||
| Additional paid in capital | 133,492,000 | 131,973,000 | ||||||
| Accumulated deficit | (114,329,000 | ) | (97,038,000 | ) | ||||
| Total stockholders’ equity | 19,751,000 | 35,511,000 | ||||||
| Total liabilities and stockholders’ equity | $ | 41,105,000 | $ | 61,521,000 | ||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(rounded to the nearest thousand dollars)
| Nine months Ended | ||||||||
| 2023 | 2022 | |||||||
| Net loss | $ | (17,327,000 | ) | $ | (9,197,000 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 3,264,000 | 3,272,000 | ||||||
| Acquisition earnout valuation adjustments | (1,905,000 | ) | (188,000 | ) | ||||
| Benefit for deferred income taxes | (104,000 | ) | — | |||||
| Share-based compensation expense | 1,626,000 | 1,212,000 | ||||||
| Impairment of goodwill | 9,813,000 | — | ||||||
| Impairment of long-lived assets | 963,000 | — | ||||||
| Provision for credit losses | — | 21,000 | ||||||
| Changes in assets and liabilities: | ||||||||
| Accounts and contract receivables | 4,299,000 | 492,000 | ||||||
| Other assets | (65,000 | ) | (868,000 | ) | ||||
| Accounts payable | 109,000 | (373,000 | ) | |||||
| Accrued expenses and other liabilities | (417,000 | ) | 1,159,000 | |||||
| Deferred revenue | (2,417,000 | ) | (251,000 | ) | ||||
| Net cash used in operating activities | (2,161,000 | ) | (4,721,000 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (47,000 | ) | (10,000 | ) | ||||
| Capitalization of software development costs | (1,562,000 | ) | (1,435,000 | ) | ||||
| Net cash used in investing activities | (1,609,000 | ) | (1,445,000 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Repayment of bank term loan | (500,000 | ) | (125,000 | ) | ||||
| Proceeds from line of credit | 500,000 | — | ||||||
| Proceeds from issuance of common stock | — | 8,316,000 | ||||||
| Payments for costs directly attributable to the issuance of common stock | — | (52,000 | ) | |||||
| Payments related to settlement of employee share-based awards | (271,000 | ) | (165,000 | ) | ||||
| Other | — | 6,000 | ||||||
| Net cash (used in) provided by financing activities | (271,000 | ) | 7,980,000 | |||||
| Net (decrease) in cash and cash equivalents | (4,041,000 | ) | 1,814,000 | |||||
| Cash and cash equivalents at beginning of period | 6,598,000 | 9,885,000 | ||||||
| Cash and cash equivalents at end of period | $ | 2,557,000 | $ | 11,699,000 | ||||
NEW BOOKINGS
(Unaudited, rounded to the nearest thousand dollars)
| Three Months Ended | Nine Months Ended | |||||||
| Software as a service | 1,937,000 | 4,778,000 | ||||||
| Maintenance and Support | - | - | ||||||
| Professional fees and licenses | 448,000 | 812,000 | ||||||
| Q3 2023 Bookings | $ | 2,385,000 | $ | 5,590,000 | ||||
| Q3 2022 Bookings | $ | 1,871,000 | $ | 15,886,000 | ||||
RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited, in thousands)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| Adjusted EBITDA Reconciliation | ||||||||||||||||
| Net Loss | $ | (11,911 | ) | $ | (3,138 | ) | $ | (17,237 | ) | $ | (9,197 | ) | ||||
| Interest expense | 266 | 198 | 781 | 519 | ||||||||||||
| Income tax (benefit) expense | (120 | ) | 9 | (59 | ) | 22 | ||||||||||
| Depreciation and amortization | 1,105 | 1,053 | 3,186 | 3,212 | ||||||||||||
| EBITDA | $ | (10,660 | ) | $ | (1,878 | ) | $ | (13,419 | ) | $ | (5,444 | ) | ||||
| Share-based compensation expense | 517 | 555 | 1,626 | 1,212 | ||||||||||||
| Impairment of goodwill | 9,813 | — | 9,813 | — | ||||||||||||
| Impairment of long-lived assets | 963 | — | 963 | — | ||||||||||||
| Non-cash valuation adjustments | (1,182 | ) | (163 | ) | (1,905 | ) | (188 | ) | ||||||||
| Acquisition-related costs, severance, and transaction-related bonuses | 213 | 387 | 389 | 1,010 | ||||||||||||
| Restructuring Charges | 749 | — | 749 | — | ||||||||||||
| Other non-recurring charges | — | (73 | ) | (33 | ) | (140 | ) | |||||||||
| Adjusted EBITDA | $ | 413 | $ | (1,172 | ) | $ | (1,817 | ) | $ | (3,550 | ) | |||||
2023 GlobeNewswire, Inc., source
